Biodeal Pharmaceuticals Ltd., a specialty pharmaceutical Contract Development and Manufacturing Organisation (CDMO), has raised a growth investment of Rs. 385 crore from RMB Capitalworks, a joint venture between Rand Merchant Bank and Capitalworks Group.

The investment marks a significant milestone in Biodeal’s growth journey and will support the company’s next phase of expansion across specialty pharmaceuticals, manufacturing capabilities and regulated markets.

With more than two decades of experience, Biodeal has established a strong position in nasal drug delivery, supported by integrated pharmaceutical development and manufacturing capabilities. 

The company serves clients across domestic and international markets and is strengthening its position as a preferred CDMO partner for global pharmaceutical companies seeking specialised manufacturing capabilities for regulated markets.

The investment will support Biodeal’s expansion across Asian markets while accelerating its growth across the CIS, Latin America, Africa and Europe.

“This investment represents much more than capital—it is a strong endorsement of the platform we have built over the past two decades,” said Anurag Kumar, CMD, Biodeal Pharmaceuticals. 

Anshuman Malur, Managing Partner, RMB Capitalworks, said the investment reflects the firm's confidence in Biodeal’s differentiated capabilities and growth potential. “Healthcare is a core focus for us, and Biodeal fits our thesis of a differentiated player primed for rapid growth. We are proud to act as true partners, working alongside the Biodeal team to strengthen governance, accelerate expansion, and build a leading pharmaceutical powerhouse,” he said.

Biodeal has delivered consistent profitable growth over the past five years, with FY26 revenue estimated to have grown by more than 60% year-on-year, alongside further expansion in EBITDA margins.

With the new investment, the company plans to strengthen its specialty pharmaceutical and manufacturing capabilities, expand its presence across international markets and build on its position as a globally trusted pharmaceutical partner. The company also intends to continue progressing towards a planned public listing as it enters its next phase of growth.